The Brazilian journal of infectious diseases, 2020-07, Vol.24 (4), p.365-367
2020
Details
- Autor(en) / Beteiligte
- Titel
- Calcineurin inhibitors revisited: A new paradigm for COVID-19?
- Ist Teil von
- The Brazilian journal of infectious diseases, 2020-07, Vol.24 (4), p.365-367
- Ort / Verlag
- Brazil: Elsevier España, S.L.U
- Erscheinungsjahr
- 2020
- Link zum Volltext
- Quelle
- Free E-Journal (出版社公開部分のみ）
- Beschreibungen/Notizen
- The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) can cause mild, moderate or severe disease (COVID-19). In severe disease, there is hyperinflammation causing severe symptoms. Severe COVID-19 is an immunological phenomenon, rather than a direct viral damage disease. Therapies for COVID-19 are all investigational therapies. In case of severe disease, treatment with a calcineurin inhibitor could be promising. In this article we explain the mechanisms of calcineurin inhibitor treatment for COVID-19, based on experiences seen in solid organ transplant recipients who suffered from COVID-19.
- Sprache
- Englisch; Portugiesisch
- Identifikatoren
- ISSN: 1413-8670, 1678-4391eISSN: 1678-4391DOI: 10.1016/j.bjid.2020.06.005Titel-ID: cdi_doaj_primary_oai_doaj_org_article_06780325bbfa48c1b755f53bb88ed444
- Format
- –
- Schlagworte
- ARDS, Betacoronavirus, Brief Communication, Calcineurin Inhibitors - therapeutic use, Coronavirus infections, Coronavirus Infections - drug therapy, Coronaviruses, COVID-19, Cytokine storm, Drug therapy, Evidence-based medicine, Humans, Hyperinflammation, Infection, INFECTIOUS DISEASES, Organ transplant recipients, Organ transplantation, Pandemics, Pneumonia, Viral - drug therapy, SARS-CoV-2, Transplant Recipients, Transplantation, Transplantation of organs, tissues, etc